Advertisement

Targeting the immune system in the treatment of bipolar disorder

  • Joshua D. RosenblatEmail author
Review

Abstract

Rationale

Immune dysfunction has been strongly implicated in the pathophysiology of bipolar disorder (BD). As such, numerous clinical trials have investigated the effects of anti-inflammatory agents in the treatment of BD.

Objectives

Review clinical studies evaluating the effects of anti-inflammatory agents in the treatment of BD during all illness phases (e.g., depression, mania, and euthymia).

Methods

Relevant databases were searched from inception to August 27, 2018 for clinical studies evaluating the effects of anti-inflammatory agents in BD.

Results

The majority of identified clinical trials evaluated adjunctive anti-inflammatory agents in the acute treatment of bipolar depression, demonstrating antidepressant effects with N-acetylcysteine (NAC), pioglitazone, minocycline, and coenzyme Q10, along with mixed evidence for omega-3s, and non-steroidal anti-inflammatory drugs (NSAIDs). The anti-manic effects of adjunctive anti-inflammatory agents have been minimally studied, with some promising preliminary results supporting potential anti-manic effects of adjunctive celecoxib and NAC. Maintenance studies are also limited, with inadequate evidence to support mood stabilizing effects of anti-inflammatories while euthymic. Regardless of illness phase, early results suggest that anti-inflammatory agents are likely most beneficial in the subgroup of BD with immune dysregulation.

Conclusions

Several proof-of-concept clinical trials have shown promising results for anti-inflammatory agents in the treatment of bipolar depression with moderate effect sizes and good tolerability. The effects of anti-inflammatory agents during manic and euthymic periods remains uncertain. Future larger studies, using stratified samples, enriched for participants with immune dysfunction, are required to determine the role of immune modulating agents in the treatment of BD.

Keywords

Bipolar disorder Depression Infliximab Probiotics Celecoxib Minocycline Non-steroidal anti-inflammatory (NSAID) N-acetylcysteine (NAC) Anti-inflammatory Immune dysfunction 

Notes

Compliance with ethical standards

Conflict of interest

None.

Supplementary material

213_2019_5175_MOESM1_ESM.pdf (204 kb)
ESM 1 (PDF 204 kb)

References

  1. Aboul-Fotouh S (2013) Coenzyme Q10 displays antidepressant-like activity with reduction of hippocampal oxidative/nitrosative DNA damage in chronically stressed rats. Pharmacol Biochem Behav 104:105–112.  https://doi.org/10.1016/j.pbb.2012.12.027 CrossRefPubMedGoogle Scholar
  2. Alam R, Abdolmaleky HM, Zhou JR (2017) Microbiome, inflammation, epigenetic alterations, and mental diseases. Am J Med Genet B Neuropsychiatr Genet 174:651–660.  https://doi.org/10.1002/ajmg.b.32567 CrossRefPubMedGoogle Scholar
  3. Al-Karawi D, Al Mamoori DA, Tayyar Y (2016) The role of curcumin administration in patients with major depressive disorder: mini meta-analysis of clinical trials. Phytother Res 30:175–183.  https://doi.org/10.1002/ptr.5524 CrossRefPubMedGoogle Scholar
  4. Arabzadeh S, Ameli N, Zeinoddini A, Rezaei F, Farokhnia M, Mohammadinejad P, Ghaleiha A, Akhondzadeh S (2015) Celecoxib adjunctive therapy for acute bipolar mania: a randomized, double-blind, placebo-controlled trial. Bipolar Disord 17:606–614.  https://doi.org/10.1111/bdi.12324 CrossRefPubMedGoogle Scholar
  5. Barbosa IG, Bauer ME, Machado-Vieira R, Teixeira AL (2014) Cytokines in bipolar disorder: paving the way for neuroprogression. Neural Plast 2014:360481.  https://doi.org/10.1155/2014/360481 CrossRefPubMedPubMedCentralGoogle Scholar
  6. Bauer IE, Galvez JF, Hamilton JE et al (2016) Lifestyle interventions targeting dietary habits and exercise in bipolar disorder: a systematic review. J Psychiatr Res 74:1–7.  https://doi.org/10.1016/j.jpsychires.2015.12.006 CrossRefPubMedGoogle Scholar
  7. Berk M, Copolov DL, Dean O, Lu K, Jeavons S, Schapkaitz I, Anderson-Hunt M, Bush AI (2008) N-acetyl cysteine for depressive symptoms in bipolar disorder—a double-blind randomized placebo-controlled trial. Biol Psychiatry 64:468–475.  https://doi.org/10.1016/j.biopsych.2008.04.022 CrossRefPubMedGoogle Scholar
  8. Berk M, Dean O, Cotton SM, Gama CS, Kapczinski F, Fernandes BS, Kohlmann K, Jeavons S, Hewitt K, Allwang C, Cobb H, Bush AI, Schapkaitz I, Dodd S, Malhi GS (2011a) The efficacy of N-acetylcysteine as an adjunctive treatment in bipolar depression: an open label trial. J Affect Disord 135:389–394.  https://doi.org/10.1016/j.jad.2011.06.005 CrossRefPubMedGoogle Scholar
  9. Berk M, Kapczinski F, Andreazza AC, Dean OM, Giorlando F, Maes M, Yücel M, Gama CS, Dodd S, Dean B, Magalhães PVS, Amminger P, McGorry P, Malhi GS (2011b) Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci Biobehav Rev 35:804–817.  https://doi.org/10.1016/j.neubiorev.2010.10.001;10.1016/j.neubiorev.2010.10.001
  10. Berk M, Dean OM, Cotton SM, Gama CS, Kapczinski F, Fernandes B, Kohlmann K, Jeavons S, Hewitt K, Moss K, Allwang C, Schapkaitz I, Cobb H, Bush AI, Dodd S, Malhi GS (2012) Maintenance N-acetyl cysteine treatment for bipolar disorder: a double-blind randomized placebo controlled trial. BMC Med 10:91.  https://doi.org/10.1186/1741-7015-10-91 CrossRefPubMedPubMedCentralGoogle Scholar
  11. Berk M, Dean O, Drexhage H, McNeil JJ, Moylan S, O'Neil A, Davey CG, Sanna L, Maes M (2013a) Aspirin: a review of its neurobiological properties and therapeutic potential for mental illness. BMC Med 11:74.  https://doi.org/10.1186/1741-7015-11-74 CrossRefPubMedPubMedCentralGoogle Scholar
  12. Berk M, Malhi GS, Gray LJ, Dean OM (2013b) The promise of N-acetylcysteine in neuropsychiatry. Trends Pharmacol Sci 34:167–177.  https://doi.org/10.1016/j.tips.2013.01.001 CrossRefPubMedGoogle Scholar
  13. Berk M, Dean OM, Cotton SM, Jeavons S, Tanious M, Kohlmann K, Hewitt K, Moss K, Allwang C, Schapkaitz I, Robbins J, Cobb H, Ng F, Dodd S, Bush AI, Malhi GS (2014) The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial. J Clin Psychiatry 75:628–636.  https://doi.org/10.4088/JCP.13m08454 CrossRefPubMedGoogle Scholar
  14. Bloch MH, Hannestad J (2012) Omega-3 fatty acids for the treatment of depression: systematic review and meta-analysis. Mol Psychiatry 17:1272–1282.  https://doi.org/10.1038/mp.2011.100 CrossRefPubMedGoogle Scholar
  15. Brietzke E, Stertz L, Fernandes BS, Kauer-Sant’Anna M, Mascarenhas M, Escosteguy Vargas A, Chies JA, Kapczinski F (2009) Comparison of cytokine levels in depressed, manic and euthymic patients with bipolar disorder. J Affect Disord 116:214–217.  https://doi.org/10.1016/j.jad.2008.12.001;10.1016/j.jad.2008.12.001
  16. Brietzke E, Mansur RB, Zugman A, Carvalho AF, Macêdo DS, Cha DS, Abílio VC, McIntyre RS (2013) Is there a role for curcumin in the treatment of bipolar disorder? Med Hypotheses 80:606–612.  https://doi.org/10.1016/j.mehy.2013.02.001 CrossRefPubMedGoogle Scholar
  17. Brietzke E, Mansur RB, Subramaniapillai M, Balanzá-Martínez V, Vinberg M, González-Pinto A, Rosenblat JD, Ho R, McIntyre RS (2018) Ketogenic diet as a metabolic therapy for mood disorders: evidence and developments. Neurosci Biobehav Rev 94:11–16.  https://doi.org/10.1016/j.neubiorev.2018.07.020 CrossRefPubMedGoogle Scholar
  18. Chiu CC, Huang SY, Chen CC, Su KP (2005) Omega-3 fatty acids are more beneficial in the depressive phase than in the manic phase in patients with bipolar I disorder. J Clin Psychiatry 66:1613–1614CrossRefGoogle Scholar
  19. Clayton EH, Hanstock TL, Hirneth SJ et al (2009) Reduced mania and depression in juvenile bipolar disorder associated with long-chain omega-3 polyunsaturated fatty acid supplementation. Eur J Clin Nutr 63:1037–1040.  https://doi.org/10.1038/ejcn.2008.81 CrossRefPubMedGoogle Scholar
  20. Cryan JF, Dinan TG (2012) Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour. Nat Rev Neurosci 13:701–712.  https://doi.org/10.1038/nrn3346 CrossRefPubMedGoogle Scholar
  21. Eaton WW, Pedersen MG, Nielsen PR, Mortensen PB (2010) Autoimmune diseases, bipolar disorder, and non-affective psychosis. Bipolar Disord 12:638–646.  https://doi.org/10.1111/j.1399-5618.2010.00853.x CrossRefPubMedPubMedCentralGoogle Scholar
  22. Ellegaard PK, Licht RW, Poulsen HE, Nielsen RE, Berk M, Dean OM, Mohebbi M, Nielsen CT (2018) Add-on treatment with N-acetylcysteine for bipolar depression: a 24-week randomized double-blind parallel group placebo-controlled multicentre trial (NACOS-study protocol). Int J Bipolar Disord 6:11.  https://doi.org/10.1186/s40345-018-0117-9 CrossRefPubMedPubMedCentralGoogle Scholar
  23. Forester BP, Zuo CS, Ravichandran C, Harper DG, du F, Kim S, Cohen BM, Renshaw PF (2012) Coenzyme Q10 effects on creatine kinase activity and mood in geriatric bipolar depression. J Geriatr Psychiatry Neurol 25:43–50.  https://doi.org/10.1177/0891988712436688 CrossRefPubMedPubMedCentralGoogle Scholar
  24. Forester BP, Harper DG, Georgakas J, Ravichandran C, Madurai N, Cohen BM (2015) Antidepressant effects of open label treatment with coenzyme Q10 in geriatric bipolar depression. J Clin Psychopharmacol 35:338–340.  https://doi.org/10.1097/JCP.0000000000000326 CrossRefPubMedPubMedCentralGoogle Scholar
  25. Frangou S, Lewis M, McCrone P (2006) Efficacy of ethyl-eicosapentaenoic acid in bipolar depression: randomised double-blind placebo-controlled study. Br J Psychiatry 188:46–50.  https://doi.org/10.1192/bjp.188.1.46 CrossRefPubMedGoogle Scholar
  26. Frangou S, Lewis M, Wollard J, Simmons A (2007) Preliminary in vivo evidence of increased N-acetyl-aspartate following eicosapentanoic acid treatment in patients with bipolar disorder. J Psychopharmacol (Oxford) 21:435–439.  https://doi.org/10.1177/0269881106067787 CrossRefGoogle Scholar
  27. Gallagher PJ, Castro V, Fava M, Weilburg JB, Murphy SN, Gainer VS, Churchill SE, Kohane IS, Iosifescu DV, Smoller JW, Perlis RH (2012) Antidepressant response in patients with major depression exposed to NSAIDs: a pharmacovigilance study. AJP 169:1065–1072.  https://doi.org/10.1176/appi.ajp.2012.11091325 CrossRefGoogle Scholar
  28. Goldsmith DR, Rapaport MH, Miller BJ (2016) A meta-analysis of blood cytokine network alterations in psychiatric patients: comparisons between schizophrenia, bipolar disorder and depression. Mol Psychiatry 21:1696–1709.  https://doi.org/10.1038/mp.2016.3 CrossRefPubMedPubMedCentralGoogle Scholar
  29. Goldstein BI, Carnethon MR, Matthews KA, McIntyre RS, Miller GE, Raghuveer G, Stoney CM, Wasiak H, McCrindle BW (2015) Major depressive disorder and bipolar disorder predispose youth to accelerated atherosclerosis and early cardiovascular disease: a scientific statement from the American Heart Association. Circulation 132:965–986.  https://doi.org/10.1161/CIR.0000000000000229 CrossRefPubMedGoogle Scholar
  30. Gracious BL, Chirieac MC, Costescu S, Finucane TL, Youngstrom EA, Hibbeln JR (2010) Randomized, placebo-controlled trial of flax oil in pediatric bipolar disorder. Bipolar Disord 12:142–154.  https://doi.org/10.1111/j.1399-5618.2010.00799.x CrossRefPubMedPubMedCentralGoogle Scholar
  31. Grande I, Berk M, Birmaher B, Vieta E (2016) Bipolar disorder. Lancet 387:1561–1572.  https://doi.org/10.1016/S0140-6736(15)00241-X CrossRefPubMedGoogle Scholar
  32. Green GA (2001) Understanding NSAIDs: from aspirin to COX-2. Clin Cornerstone 3:50–60CrossRefGoogle Scholar
  33. Grosso G, Pajak A, Marventano S, Castellano S, Galvano F, Bucolo C, Drago F, Caraci F (2014) Role of omega-3 fatty acids in the treatment of depressive disorders: a comprehensive meta-analysis of randomized clinical trials. PLoS One 9:e96905.  https://doi.org/10.1371/journal.pone.0096905 CrossRefPubMedPubMedCentralGoogle Scholar
  34. Hirashima F, Parow AM, Stoll AL et al (2004) Omega-3 fatty acid treatment and T(2) whole brain relaxation times in bipolar disorder. Am J Psychiatry 161:1922–1924.  https://doi.org/10.1176/appi.ajp.161.10.1922 CrossRefPubMedGoogle Scholar
  35. Hope S, Dieset I, Agartz I, Steen NE, Ueland T, Melle I, Aukrust P, Andreassen OA (2011) Affective symptoms are associated with markers of inflammation and immune activation in bipolar disorders but not in schizophrenia. J Psychiatr Res 45:1608–1616.  https://doi.org/10.1016/j.jpsychires.2011.08.003 CrossRefPubMedGoogle Scholar
  36. Horrobin DF, Lieb J (1981) A biochemical basis for the actions of lithium on behaviour and on immunity: relapsing and remitting disorders of inflammation and immunity such as multiple sclerosis or recurrent herpes as manic-depression of the immune system. Med Hypotheses 7:891–905CrossRefGoogle Scholar
  37. Husain MI, Strawbridge R, Stokes PR, Young AH (2017) Anti-inflammatory treatments for mood disorders: Systematic review and meta-analysis. J Psychopharmacol (Oxford, England) 31(9):1137–1148.  https://doi.org/10.1177/0269881117725711 CrossRefGoogle Scholar
  38. Judd LL, Akiskal HS, Schettler PJ, Endicott J, Maser J, Solomon DA, Leon AC, Rice JA, Keller MB (2002) The long-term natural history of the weekly symptomatic status of bipolar I disorder. Arch Gen Psychiatry 59:530–537.  https://doi.org/10.1001/archpsyc.59.6.530 CrossRefPubMedGoogle Scholar
  39. Kargar M, Yoosefi A, Akhondzadeh S, Artonian V, Ashouri A, Ghaeli P (2015) Effect of adjunctive celecoxib on BDNF in manic patients undergoing electroconvulsive therapy: a randomized double blind controlled trial. Pharmacopsychiatry 48:268–273.  https://doi.org/10.1055/s-0035-1559667 CrossRefPubMedGoogle Scholar
  40. Kashani L, Omidvar T, Farazmand B, Modabbernia A, Ramzanzadeh F, Tehraninejad ES, Ashrafi M, Tabrizi M, Akhondzadeh S (2013) Does pioglitazone improve depression through insulin-sensitization? Results of a randomized double-blind metformin-controlled trial in patients with polycystic ovarian syndrome and comorbid depression. Psychoneuroendocrinology 38:767–776.  https://doi.org/10.1016/j.psyneuen.2012.08.010 CrossRefPubMedGoogle Scholar
  41. Keck PE, Mintz J, McElroy SL et al (2006) Double-blind, randomized, placebo-controlled trials of ethyl-eicosapentanoate in the treatment of bipolar depression and rapid cycling bipolar disorder. Biol Psychiatry 60:1020–1022.  https://doi.org/10.1016/j.biopsych.2006.03.056 CrossRefPubMedGoogle Scholar
  42. Kemp DE, Ismail-Beigi F, Calabrese JR (2009) Antidepressant response associated with pioglitazone: support for an overlapping pathophysiology between major depression and metabolic syndrome. Am J Psychiatry 166:619.  https://doi.org/10.1176/appi.ajp.2008.08081195 CrossRefPubMedPubMedCentralGoogle Scholar
  43. Kemp DE, Ismail-Beigi F, Ganocy SJ, Conroy C, Gao K, Obral S, Fein E, Findling RL, Calabrese JR (2012) Use of insulin sensitizers for the treatment of major depressive disorder: a pilot study of pioglitazone for major depression accompanied by abdominal obesity. J Affect Disord 136:1164–1173.  https://doi.org/10.1016/j.jad.2011.06.033 CrossRefPubMedGoogle Scholar
  44. Kemp DE, Schinagle M, Gao K, Conroy C, Ganocy SJ, Ismail-Beigi F, Calabrese JR (2014) PPAR-gamma agonism as a modulator of mood: proof-of-concept for pioglitazone in bipolar depression. CNS Drugs 28:571–581.  https://doi.org/10.1007/s40263-014-0158-2 CrossRefPubMedPubMedCentralGoogle Scholar
  45. Kenis G, Maes M (2002) Effects of antidepressants on the production of cytokines. Int J Neuropsychopharmacol 5:401–412.  https://doi.org/10.1017/S1461145702003164 CrossRefPubMedGoogle Scholar
  46. Kessing LV, Vradi E, Andersen PK (2015) Life expectancy in bipolar disorder. Bipolar Disord 17:543–548.  https://doi.org/10.1111/bdi.12296 CrossRefPubMedGoogle Scholar
  47. Kim YK, Jung HG, Myint AM, Kim H, Park SH (2007) Imbalance between pro-inflammatory and anti-inflammatory cytokines in bipolar disorder. J Affect Disord 104:91–95.  https://doi.org/10.1016/j.jad.2007.02.018 CrossRefPubMedGoogle Scholar
  48. Kohler O, Benros ME, Nordentoft M et al (2014) Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA Psychiatry (Chicago).  https://doi.org/10.1001/jamapsychiatry.2014.1611
  49. Köhler-Forsberg O, Sylvia L, Thase M, Calabrese JR, Deckersbach T, Tohen M, Bowden CL, McInnis M, Kocsis JH, Friedman ES, Ketter TA, McElroy S, Shelton RC, Nierenberg AA (2017) Nonsteroidal anti-inflammatory drugs (NSAIDs) and paracetamol do not affect 6-month mood-stabilizing treatment outcome among 482 patients with bipolar disorder. Depress Anxiety 34:281–290.  https://doi.org/10.1002/da.22601 CrossRefPubMedGoogle Scholar
  50. Köhler-Forsberg O, Sylvia L, Deckersbach T, Ostacher MJ, McInnis M, Iosifescu D, Bowden C, McElroy S, Calabrese J, Thase M, Shelton RC, Tohen M, Kocsis J, Friedman E, Ketter T, Nierenberg AA (2018) Clinically relevant and simple immune system measure is related to symptom burden in bipolar disorder. Acta Neuropsychiatr 30:297–305.  https://doi.org/10.1017/neu.2017.34 CrossRefPubMedGoogle Scholar
  51. Levine J, Cholestoy A, Zimmerman J (1996) Possible antidepressant effect of minocycline. Am J Psychiatry 153:582PubMedGoogle Scholar
  52. Maddu N, Raghavendra PB (2015) Review of lithium effects on immune cells. Immunopharmacol Immunotoxicol 37:111–125.  https://doi.org/10.3109/08923973.2014.998369 CrossRefPubMedGoogle Scholar
  53. Maes M, Bosmans E, Calabrese J, Smith R, Meltzer HY (1995) Interleukin-2 and interleukin-6 in schizophrenia and mania: effects of neuroleptics and mood stabilizers. J Psychiatr Res 29:141–152CrossRefGoogle Scholar
  54. Magalhaes PV, Dean OM, Bush AI et al (2011a) N-acetylcysteine for major depressive episodes in bipolar disorder. Rev Bras Psiquiatr 33:374–378CrossRefGoogle Scholar
  55. Magalhaes PV, Dean OM, Bush AI et al (2011b) N-acetyl cysteine add-on treatment for bipolar II disorder: a subgroup analysis of a randomized placebo-controlled trial. J Affect Disord 129:317–320.  https://doi.org/10.1016/j.jad.2010.08.001 CrossRefPubMedGoogle Scholar
  56. Magalhaes PV, Dean OM, Bush AI et al (2013) A preliminary investigation on the efficacy of N-acetyl cysteine for mania or hypomania. Aust N Z J Psychiatry 47:564–568.  https://doi.org/10.1177/0004867413481631 CrossRefPubMedGoogle Scholar
  57. McElroy SL, Keck PE (2014) Metabolic syndrome in bipolar disorder: a review with a focus on bipolar depression. J Clin Psychiatry 75:46–61.  https://doi.org/10.4088/JCP.13r08634 CrossRefPubMedGoogle Scholar
  58. McNamara RK, Strawn JR (2013) Role of long-chain Omega-3 fatty acids in psychiatric practice. PharmaNutrition 1:41–49.  https://doi.org/10.1016/j.phanu.2012.10.004 CrossRefPubMedGoogle Scholar
  59. Mehrpooya M, Yasrebifar F, Haghighi M, Mohammadi Y, Jahangard L (2018) Evaluating the effect of coenzyme Q10 augmentation on treatment of bipolar depression: a double-blind controlled clinical trial. J Clin Psychopharmacol 38:460–466.  https://doi.org/10.1097/JCP.0000000000000938 CrossRefPubMedGoogle Scholar
  60. Miller AH, Maletic V, Raison CL (2009) Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 65:732–741.  https://doi.org/10.1016/j.biopsych.2008.11.029 CrossRefPubMedPubMedCentralGoogle Scholar
  61. Miura T, Noma H, Furukawa TA, Mitsuyasu H, Tanaka S, Stockton S, Salanti G, Motomura K, Shimano-Katsuki S, Leucht S, Cipriani A, Geddes JR, Kanba S (2014) Comparative efficacy and tolerability of pharmacological treatments in the maintenance treatment of bipolar disorder: a systematic review and network meta-analysis. Lancet Psychiatry 1:351–359.  https://doi.org/10.1016/S2215-0366(14)70314-1 CrossRefPubMedGoogle Scholar
  62. Modabbernia A, Taslimi S, Brietzke E, Ashrafi M (2013) Cytokine alterations in bipolar disorder: a meta-analysis of 30 studies. Biol Psychiatry 74:15–25.  https://doi.org/10.1016/j.biopsych.2013.01.007 CrossRefPubMedGoogle Scholar
  63. Montgomery P, Richardson AJ (2008) Omega-3 fatty acids for bipolar disorder. Cochrane Database Syst Rev:CD005169.  https://doi.org/10.1002/14651858.CD005169.pub2
  64. Mooney JJ, Brady RO (2018) Lithium + colchicine: a potential strategy to reduce pro-inflammatory effects of Lithium treatment. J Clin Psychopharmacol 38:80–85.  https://doi.org/10.1097/JCP.0000000000000830 CrossRefPubMedGoogle Scholar
  65. Morris G, Anderson G, Berk M, Maes M (2013) Coenzyme Q10 depletion in medical and neuropsychiatric disorders: potential repercussions and therapeutic implications. Mol Neurobiol 48:883–903.  https://doi.org/10.1007/s12035-013-8477-8 CrossRefPubMedGoogle Scholar
  66. Mousavi SY, Khezri R, Karkhaneh-Yousefi MA, Mohammadinejad P, Gholamian F, Mohammadi MR, Zeinoddini A, Akhondzadeh S (2017) A randomized, double-blind placebo-controlled trial on effectiveness and safety of celecoxib adjunctive therapy in adolescents with acute bipolar mania. J Child Adolesc Psychopharmacol 27:494–500.  https://doi.org/10.1089/cap.2016.0207 CrossRefPubMedGoogle Scholar
  67. Muller N (2010) COX-2 inhibitors as antidepressants and antipsychotics: clinical evidence. Curr Opin Investig Drugs 11:31–42PubMedGoogle Scholar
  68. Nassar A, Azab AN (2014) Effects of lithium on inflammation. ACS Chem Neurosci 5:451–458.  https://doi.org/10.1021/cn500038f CrossRefPubMedPubMedCentralGoogle Scholar
  69. Nery FG, Monkul ES, Hatch JP, Fonseca M, Zunta-Soares GB, Frey BN, Bowden CL, Soares JC (2008) Celecoxib as an adjunct in the treatment of depressive or mixed episodes of bipolar disorder: a double-blind, randomized, placebo-controlled study. Hum Psychopharmacol 23:87–94.  https://doi.org/10.1002/hup.912 CrossRefPubMedGoogle Scholar
  70. Nitta M, Kishimoto T, Müller N, Weiser M, Davidson M, Kane JM, Correll CU (2013) Adjunctive use of nonsteroidal anti-inflammatory drugs for schizophrenia: a meta-analytic investigation of randomized controlled trials. Schizophr Bull 39:1230–1241.  https://doi.org/10.1093/schbul/sbt070 CrossRefPubMedPubMedCentralGoogle Scholar
  71. Osher Y, Bersudsky Y, Belmaker RH (2005) Omega-3 eicosapentaenoic acid in bipolar depression: report of a small open-label study. J Clin psychiatry 66:726–729CrossRefGoogle Scholar
  72. Raison CL, Miller AH (2013) Malaise, melancholia and madness: the evolutionary legacy of an inflammatory bias. Brain Behav Immun 31:1–8.  https://doi.org/10.1016/j.bbi.2013.04.009 CrossRefPubMedPubMedCentralGoogle Scholar
  73. Raison CL, Rutherford RE, Woolwine BJ, Shuo C, Schettler P, Drake DF, Haroon E, Miller AH (2013) A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA Psychiatry (Chicago) 70:31–41.  https://doi.org/10.1001/2013.jamapsychiatry.4 CrossRefGoogle Scholar
  74. Raison CL, Pikalov A, Siu C, Tsai J, Koblan K, Loebel A (2018) C-reactive protein and response to lurasidone in patients with bipolar depression. Brain Behav Immun 73:717–724.  https://doi.org/10.1016/j.bbi.2018.08.009 CrossRefPubMedGoogle Scholar
  75. Rapaport MH, Nierenberg AA, Schettler PJ, Kinkead B, Cardoos A, Walker R, Mischoulon D (2016) Inflammation as a predictive biomarker for response to omega-3 fatty acids in major depressive disorder: a proof-of-concept study. Mol Psychiatry 21:71–79.  https://doi.org/10.1038/mp.2015.22 CrossRefPubMedGoogle Scholar
  76. Rios AC, Maurya PK, Pedrini M, Zeni-Graiff M, Asevedo E, Mansur RB, Wieck A, Grassi-Oliveira R, McIntyre RS, Hayashi MAF, Brietzke E (2017) Microbiota abnormalities and the therapeutic potential of probiotics in the treatment of mood disorders. Rev Neurosci 28:739–749.  https://doi.org/10.1515/revneuro-2017-0001 CrossRefPubMedGoogle Scholar
  77. Rosenblat JD, McIntyre RS (2015) Are medical comorbid conditions of bipolar disorder due to immune dysfunction? Acta Psychiatr Scand 132:180–191.  https://doi.org/10.1111/acps.12414 CrossRefPubMedGoogle Scholar
  78. Rosenblat JD, McIntyre RS (2016) Bipolar disorder and inflammation. Psychiatr Clin N Am 39:125–137.  https://doi.org/10.1016/j.psc.2015.09.006 CrossRefGoogle Scholar
  79. Rosenblat JD, McIntyre RS (2017) Bipolar disorder and immune dysfunction: epidemiological findings, proposed pathophysiology and clinical implications. Brain Sci 7.  https://doi.org/10.3390/brainsci7110144
  80. Rosenblat JD, McIntyre RS (2018) Efficacy and tolerability of minocycline for depression: a systematic review and meta-analysis of clinical trials. J Affect Disord 227:219–225.  https://doi.org/10.1016/j.jad.2017.10.042 CrossRefPubMedGoogle Scholar
  81. Rosenblat JD, Cha DS, Mansur RB, McIntyre RS (2014) Inflamed moods: a review of the interactions between inflammation and mood disorders. Prog Neuro-Psychopharmacol Biol Psychiatry 53:23–34.  https://doi.org/10.1016/j.pnpbp.2014.01.013 CrossRefGoogle Scholar
  82. Rosenblat JD, Brietzke E, Mansur RB, Maruschak NA, Lee Y, McIntyre RS (2015) Inflammation as a neurobiological substrate of cognitive impairment in bipolar disorder: evidence, pathophysiology and treatment implications. J Affect Disord 188:149–159.  https://doi.org/10.1016/j.jad.2015.08.058 CrossRefPubMedGoogle Scholar
  83. Rosenblat JD, Kakar R, Berk M, Kessing LV, Vinberg M, Baune BT, Mansur RB, Brietzke E, Goldstein BI, McIntyre RS (2016) Anti-inflammatory agents in the treatment of bipolar depression: a systematic review and meta-analysis. Bipolar Disord 18:89–101.  https://doi.org/10.1111/bdi.12373 CrossRefPubMedGoogle Scholar
  84. Saroukhani S, Emami-Parsa M, Modabbernia A, Ashrafi M, Farokhnia M, Hajiaghaee R, Akhondzadeh S (2013) Aspirin for treatment of lithium-associated sexual dysfunction in men: randomized double-blind placebo-controlled study. Bipolar Disord 15:650–656.  https://doi.org/10.1111/bdi.12108 CrossRefPubMedGoogle Scholar
  85. Sarris J, Mischoulon D, Schweitzer I (2011) Adjunctive nutraceuticals with standard pharmacotherapies in bipolar disorder: a systematic review of clinical trials. Bipolar Disord 13:454–465.  https://doi.org/10.1111/j.1399-5618.2011.00945.x CrossRefPubMedGoogle Scholar
  86. Sarris J, Mischoulon D, Schweitzer I (2012) Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression. J Clin Psychiatry 73:81–86.  https://doi.org/10.4088/JCP.10r06710 CrossRefPubMedGoogle Scholar
  87. Savitz J, Preskorn S, Teague TK, Drevets D, Yates W, Drevets W (2012) Minocycline and aspirin in the treatment of bipolar depression: a protocol for a proof-of-concept, randomised, double-blind, placebo-controlled, 2x2 clinical trial. BMJ Open 2:e000643.  https://doi.org/10.1136/bmjopen-2011-000643 CrossRefPubMedPubMedCentralGoogle Scholar
  88. Savitz JB, Teague TK, Misaki M, Macaluso M, Wurfel BE, Meyer M, Drevets D, Yates W, Gleason O, Drevets WC, Preskorn SH (2018) Treatment of bipolar depression with minocycline and/or aspirin: an adaptive, 2×2 double-blind, randomized, placebo-controlled, phase IIA clinical trial. Transl Psychiatry 8:27.  https://doi.org/10.1038/s41398-017-0073-7 CrossRefPubMedPubMedCentralGoogle Scholar
  89. Selle V, Schalkwijk S, Vazquez GH, Baldessarini RJ (2014) Treatments for acute bipolar depression: meta-analyses of placebo-controlled, monotherapy trials of anticonvulsants, lithium and antipsychotics. Pharmacopsychiatry 47:43–52.  https://doi.org/10.1055/s-0033-1363258 CrossRefPubMedGoogle Scholar
  90. Sepanjnia K, Modabbernia A, Ashrafi M, Modabbernia MJ, Akhondzadeh S (2012) Pioglitazone adjunctive therapy for moderate-to-severe major depressive disorder: randomized double-blind placebo-controlled trial. Neuropsychopharmacology 37:2093–2100.  https://doi.org/10.1038/npp.2012.58 CrossRefPubMedPubMedCentralGoogle Scholar
  91. Skvarc DR, Dean OM, Byrne LK, Gray L, Lane S, Lewis M, Fernandes BS, Berk M, Marriott A (2017) The effect of N-acetylcysteine (NAC) on human cognition—a systematic review. Neurosci Biobehav Rev 78:44–56.  https://doi.org/10.1016/j.neubiorev.2017.04.013 CrossRefPubMedGoogle Scholar
  92. Soczynska JK, Mansur RB, Brietzke E, Swardfager W, Kennedy SH, Woldeyohannes HO, Powell AM, Manierka MS, McIntyre RS (2012) Novel therapeutic targets in depression: minocycline as a candidate treatment. Behav Brain Res 235:302–317.  https://doi.org/10.1016/j.bbr.2012.07.026 CrossRefPubMedGoogle Scholar
  93. Soczynska JK, Kennedy SH, Alsuwaidan M, Mansur RB, Li M, McAndrews MP, Brietzke E, Woldeyohannes HO, Taylor VH, McIntyre RS (2017) A pilot, open-label, 8-week study evaluating the efficacy, safety and tolerability of adjunctive minocycline for the treatment of bipolar I/II depression. Bipolar Disord 19:198–213.  https://doi.org/10.1111/bdi.12496 CrossRefPubMedGoogle Scholar
  94. Stertz L, Magalhaes PV, Kapczinski F (2013) Is bipolar disorder an inflammatory condition? The relevance of microglial activation. Curr Opin Psychiatry 26:19–26.  https://doi.org/10.1097/YCO.0b013e32835aa4b4 CrossRefPubMedGoogle Scholar
  95. Stolk P, Souverein PC, Wilting I, Leufkens HGM, Klein DF, Rapoport SI, Heerdink ER (2010) Is aspirin useful in patients on lithium? A pharmacoepidemiological study related to bipolar disorder. Prostaglandins Leukot Essent Fat Acids 82:9–14.  https://doi.org/10.1016/j.plefa.2009.10.007 CrossRefGoogle Scholar
  96. Stoll AL, Severus WE, Freeman MP, Rueter S, Zboyan HA, Diamond E, Cress KK, Marangell LB (1999) Omega 3 fatty acids in bipolar disorder: a preliminary double-blind, placebo-controlled trial. Arch Gen Psychiatry 56:407–412CrossRefGoogle Scholar
  97. Sutterland AL, Fond G, Kuin A, Koeter MWJ, Lutter R, van Gool T, Yolken R, Szoke A, Leboyer M, de Haan L (2015) Beyond the association. Toxoplasma gondii in schizophrenia, bipolar disorder, and addiction: systematic review and meta-analysis. Acta Psychiatr Scand 132:161–179.  https://doi.org/10.1111/acps.12423 CrossRefPubMedGoogle Scholar
  98. van den Ameele S, van Diermen L, Staels W, Coppens V, Dumont G, Sabbe B, Morrens M (2016) The effect of mood-stabilizing drugs on cytokine levels in bipolar disorder: a systematic review. J Affect Disord 203:364–373.  https://doi.org/10.1016/j.jad.2016.06.016 CrossRefPubMedGoogle Scholar
  99. Zeinoddini A, Sorayani M, Hassanzadeh E, Arbabi M, Farokhnia M, Salimi S, Ghaleiha A, Akhondzadeh S (2015) Pioglitazone adjunctive therapy for depressive episode of bipolar disorder: a randomized, double-blind, placebo-controlled trial. Depress Anxiety 32:167–173.  https://doi.org/10.1002/da.22340 CrossRefPubMedGoogle Scholar
  100. Zheng W, Zhang Q-E, Cai D-B, Yang XH, Qiu Y, Ungvari GS, Ng CH, Berk M, Ning YP, Xiang YT (2018) N-acetylcysteine for major mental disorders: a systematic review and meta-analysis of randomized controlled trials. Acta Psychiatr Scand 137:391–400.  https://doi.org/10.1111/acps.12862 CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Mood Disorder Psychopharmacology Unit, Department of Psychiatry and Pharmacology, University Health NetworkUniversity of TorontoTorontoCanada

Personalised recommendations